Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes
Authors:
Open Access
- 19 July 2021
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 32 (13-14) , 682-693
Abstract
The suprachoroid is a potential space located between the sclera and choroid of the eye, which provides a novel route for ocular drug or viral vector delivery. Suprachoroidal injection of adeno-associated virus (AAV)8 using transscleral microneedles enables widespread transgene expression in eyes of nonhuman primates, but may cause intraocular inflammation. We characterized the host humoral and cellular immune responses after suprachoroidal delivery of AAV8 expressing green fluorescent protein (GFP) in rhesus macaques, and found that it can induce mild chorioretinitis that resolves after systemic corticosteroid administration, with recovery of photoreceptor morphology, but persistent immune cell infiltration after 3 months, corresponding to a loss of GFP expression from retinal pigment epithelial cells, but persistent expression in scleral fibroblasts. Suprachoroidal AAV8 triggered B cell and T cell responses against GFP, but only mild antibody responses to the viral capsid compared to intravitreal injections of the same vector and dose. Systemic biodistribution studies showed lower AAV8 levels in liver and spleen after suprachoroidal injection compared with intravitreal delivery. Our findings suggest that suprachoroidal AAV8 primarily triggers host immune responses to GFP, likely due to sustained transgene expression in scleral fibroblasts outside the blood–retinal barrier, but elicits less humoral immune reactivity to the viral capsid than intravitreal delivery due to lower egress into systemic circulation. As GFP is not native to primates and not a clinically relevant transgene, suprachoroidal AAV delivery of human transgenes may have significant translational potential for retinal gene therapy.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- Effector CD8 T cell trafficking within the liverMolecular Immunology, 2013
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse RetinaMolecular Therapy, 2011
- Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF MoleculeMolecular Therapy, 2011
- Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow MicroneedlesPharmaceutical Research, 2010
- Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisNew England Journal of Medicine, 2009
- Subretinal delivery of adeno‐associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent miceThe Journal of Gene Medicine, 2009
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Loss of Siglec expression on T lymphocytes during human evolutionProceedings of the National Academy of Sciences, 2006